نتائج البحث - "A. Kulikov Yu."

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 15, No 1 (2022); 73-86 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 15, No 1 (2022); 73-86 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: iron deficiency anemia, patient blood management, iron supplements, pharmacoeconomics, cost-effectiveness analysis, железодефицитная анемия, менеджмент крови пациентов, препараты железа, фармакоэкономика, анализ «затраты–эффективность»

وصف الملف: application/pdf

العلاقة: https://www.pharmacoeconomics.ru/jour/article/view/660/416Test; Peyrin-Biroulet L., Williet N., Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015; 102 (6): 1585–94. https://doi.org/10.3945/ajcn.114.103366Test.; Хофманн А., Аапро М., Федорова Т.А. и др. Менеджмент крови пациентов в онкологии в Российской Федерации. Резолюция во имя улучшения оказания помощи онкологическим больным. Современная онкология. 2020; 22 (3): 59–78. https://doi.org/10.26442/18151434.2020.3.200340Test.; Клинические рекомендации. Железодефицитная анемия. 2021 год. URL: https://labdep.com/storage/editor/JDA_2021_klin_rek.pdfTest (дата обращения 05.02.2022); Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Фармакоэкономика. Учебное пособие. 2-е изд. Ростов-на Дону: Феникс; 2018: 237 с.; Торшин И.Ю., Громова О.А. Экспертный анализ данных в молекулярной фармакологии. М.: МЦНМО; 2012: 748 с.; Маркова И.В, Афанасьев В.В., Цыбулькин Э.К. Клиническая токсикология детей и подростков. СПб.: Интермедика; 1999: 399 c.; Jahn M.R., Andreasen H.B., Fütterer S., et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78 (3): 480–91. https://doi.org/10.1016/j.ejpb.2011.03.016Test.; Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ruTest (дата обращения 02.09.2021).; Gordon M., Sinopoulou V., Iheozor-Ejiofor Z., et al. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev. 2021; 1 (1): CD013529. https://doi.org/10.1002/14651858.CD013529.pub2Test.; Shin H.W., Go D.Y., Lee S.W., et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis. Medicine (Baltimore). 2021; 100 (20): e24571. https://doi.org/10.1097/MD.0000000000024571Test.; Aksan A., Işık H., Radeke H.H., et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 45 (10): 1303–18. https://doi.org/10.1111/apt.14043Test.; Pollock R.F., Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019; 12 (2): 129–36. https://doi.org/10.1080/17474086.2019.1575202Test.; Официальный сайт Единой информационной системы в сфере закупок. URL: https://zakupki.gov.ruTest (дата обращения 03.09.2021).; Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень жизненно необходимых и важнейших лекарственных препаратов. URL: https://minzdrav.gov.ru/opendata/7707778246-gosreestrpredelnyhotpusknyhcen/visualTest (дата обращения 02.09.2021).; Schaefer B., Tobiasch M., Viveiros A., et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021; 87 (5): 2256–73. https://doi.org/10.1111/bcp.14643Test.; Pollock R.F., Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020; 23 (7): 751–9. https://doi.org/10.1080/13696998.2020.1745535Test.; Городская поликлиника № 2 Департамента здравоохранения города Москвы. Стоимость услуг. URL: https://gp2dzm.ru/stoimostuslugTest (дата обращения 04.09.2021).; Trentino K.M., Mace H., Symons K., et al. Associations of a preoperative anemia and suboptimal iron stores screening and management clinic in colorectal surgery with hospital cost, reimbursement, and length of stay: a net cost analysis. Anish Analog. 2021; 132 (2): 344–52. https://doi.org/10.1213/ANE.0000000000005241Test.; Багова М.О., Магомедова А.У., Кравченко С.К. и др. Фармакоэкономический анализ комбинированной иммунохимиотерапии R-DA-EPOCH и R-mNHL-BFM-90 у пациентов с прогностически неблагоприятной диффузной В-крупноклеточной лимфомой в рамках рандомизированного многоцентрового клинического исследования ДВККЛ-2015. Клиническая онкогематология. 2021; 14 (3): 321–32. https://doi.org/10.21320/2500-2139-2021-14-3-321-332Test.; Серов В.Н. (ред.) Диагностика и лечение периоперационной анемии и дефицита железа у хирургических пациентов: методическое руководство. Чебоксары: ИД «Среда»; 2021: 60 с.; Прайс-лист сети лабораторий Invitro. URL: https://www.invitro.ruTest (дата обращения 04.09.2021).; Kulnigg S., Stoinov S., Simanenkov V., et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103 (5): 1182–92. https://doi.org/10.1111/j.1572-0241.2007.01744.xTest.; Lima J., Gago P., Rocha M., et al. Role of intravenous iron in the treatment of anemia in patients with gastrointestinal tract tumors undergoing chemotherapy: a single-center, observational study. Int J Gen Med. 2018; 11: 331–6. https://doi.org/10.2147/IJGM.S165947Test.; Slaats J., ten Oever J., van der Veerdonk F.L., Netea M.G. IL-1β/ IL-6/СRP and IL-18/ferritin: distinct inflammatory programs in infections. PloS Pathog. 2016; 12 (12): e1005973. https://doi.org/10.1371/journal.ppat.1005973Test.; Торшин И.Ю., Громова О.А. Микронутриенты против коронавирусов. М.: ГЭОТАР-Медиа; 2020: 112 с.; Bach M., Geisel T., Martin J., et al. Efficacy and safety of intravenous ferric carboxymaltose in geriatric inpatients at a German Tertiary University Teaching Hospital: a retrospective observational cohort study of clinical practice. Anemia. 2015; 2015: 647930. https://doi.org/10.1155/2015/647930Test.; Keeler B.D., Simpson J.A., Ng S., et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 2014; 16 (10): 794– 800. https://doi.org/10.1111/codi.12683Test.; Moore R.A., Gaskell H., Rose P., Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011; 11: 4. https://doi.org/10.1186/1471-2326-11-4Test.; Ifie E., Oyibo S.O., Joshi H., Akintade O. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019; 2019 (1): 19–0065. https://doi.org/10.1530/EDM-19-0065Test.; Jensen G., Gøransson L.G., Fernström A., et al. Treatment of iron deficiency in patients with chronic kidney disease: a prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol. 2019; 91 (4): 246–53. https://doi.org/10.5414/CN109474Test.; Wikström B., Bhandari S., Barany P., et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011; 24 (5): 589–96. https://doi.org/10.5301/JN.2011.6248Test.; Kalra P.A., Bhandari S., Saxena S., et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016; 31 (4): 646–55. https://doi.org/10.1093/ndt/gfv293Test.; Clemmensen S.Z., Kragholm K.H., Melgaard D., et al. Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery: an observational study. J Orthop Surg Res. 2021; 16 (1): 320. https://doi.org/10.1186/s13018-021-02462-xTest.; Goh H.J., Lee K.S., Kim T.H., et al. Intravenous iron isomaltoside 1000 reduces postoperative anemia in patients undergoing elective urologic surgery and those with urosepsis. Drug Des Devel Ther. 2020; 14: 5679–87. https://doi.org/10.2147/DDDT.S276904Test.; Johansson P.I., Rasmussen A.S., Thomsen L.L. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015; 109 (3): 257–66. https://doi.org/10.1111/vox.12278Test.; Holm C., Thomsen L.L., Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med. 2019; 32 (17): 2797–804. https://doi.org/10.1080/14767058.2018.1449205Test.; Gybel-Brask M., Seeberg J., Thomsen L.L., Johansson P.I. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion. 2018; 58 (4): 974–81. https://doi.org/10.1111/trf.14521Test.; Dahlerup J.F., Jacobsen B.A., van der Woude J., et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016; 51 (11): 1332–8. https://doi.org/10.1080/00365521.2016.1196496Test.; Федеральная антимонопольная служба. Предельные размеры оптовых надбавок и предельные размеры розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах Российской Федерации (данные по состоянию на 21.10.2020). URL: https://fas.gov.ru/documents/687272Test (дата обращения 01.07.2021).; https://www.pharmacoeconomics.ru/jour/article/view/660Test